ULTRAGENYX PHARMACEUTICAL IN
RARENASDAQTrading Snapshot
- Day Range
- $15.22 – $15.55
- 52-Week Range
- $12.73 – $39.89
- Volume
- $6.10B
- Avg Volume
- $6.92B
- Shares Outstanding
- 98.5M
- Next Earnings
- Nov 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $673M
- Last Q Revenue
- $214M
- P/E Ratio
- —
- P/S Ratio
- 2.0x
- EPS (TTM)
- $-5.84
- Dividend Yield
- —
- Dilution (1yr)
- +4.4%
Why Investors Own RARE
- ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ULTRAGENYX PHARMACEUTICAL IN
RARE
StockOtter · stockotter.spaceAbout ULTRAGENYX PHARMACEUTICAL IN
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE - Get Free Report) have received an average rating of "Hold" from the twenty-one ratings firms that are currently covering the firm, MarketBeat.com reports. One inve
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE).
JAGUAR URANIUM REPORTS RARE EARTH OXIDES ASSOCIATED WITH URANIUM-PHOSPHATE-VANADIUM MINERALIZATION AT THE BERLIN ASSET IN COLOMBIA
Selected retained-core intervals contain rare earth elements, including neodymium, praseodymium, terbium and dysprosium (magnet rare earths), together with uranium, vanadium and phosphate mineralization. 0.63 m @ 3,570 p
ULTRA-RARE MCA CENTENAIRE, MONACO'S FIRST SUPERCAR, OFFERED AT BROAD ARROW'S 2026 ZOUTE CONCOURS AUCTION
Monte Carlo Automotive (MCA) Centenaire was the first road car with a carbon fibre monocoque chassis and is powered by a 5.2-litre V12 from the Lamborghini Countach 5000 QV | This example of Monaco's first supercar, crea
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.